BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

758 related articles for article (PubMed ID: 16933750)

  • 1. Antifungal susceptibility of Cryptococcus neoformans to amphotericin B and fluconazole.
    Khyriem AB; Sujatha S; Parija SC
    Indian J Pathol Microbiol; 2006 Apr; 49(2):307-8. PubMed ID: 16933750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increasing in vitro resistance to fluconazole in Cryptococcus neoformans Cambodian isolates: April 2000 to March 2002.
    Sar B; Monchy D; Vann M; Keo C; Sarthou JL; Buisson Y
    J Antimicrob Chemother; 2004 Aug; 54(2):563-5. PubMed ID: 15254027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro susceptibilities of Malaysian clinical isolates of Cryptococcus neoformans var. grubii and Cryptococcus gattii to five antifungal drugs.
    Tay ST; Tanty Haryanty T; Ng KP; Rohani MY; Hamimah H
    Mycoses; 2006 Jul; 49(4):324-30. PubMed ID: 16784448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro antifungal activities of amphotericin B, 5-fluorocytosine, fluconazole and itraconazole against Cryptococcus neoformans isolated from cerebrospinal fluid and blood from patients in Serbia.
    Trpković A; Pekmezović M; Barać A; Crnčević Radović L; Arsić Arsenijević V
    J Mycol Med; 2012 Sep; 22(3):243-8. PubMed ID: 23518082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antifungal susceptibilities of Cryptococcus neoformans cerebrospinal fluid isolates and clinical outcomes of cryptococcal meningitis in HIV-infected patients with/without fluconazole prophylaxis.
    Manosuthi W; Sungkanuparph S; Thongyen S; Chumpathat N; Eampokalap B; Thawornwan U; Foongladda S
    J Med Assoc Thai; 2006 Jun; 89(6):795-802. PubMed ID: 16850679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antifungal drug susceptibility of Cryptococcus neoformans from clinical sources in Nairobi, Kenya.
    Bii CC; Makimura K; Abe S; Taguchi H; Mugasia OM; Revathi G; Wamae NC; Kamiya S
    Mycoses; 2007 Jan; 50(1):25-30. PubMed ID: 17302744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serotypes of clinical cerebrospinal fluid Cryptococcus neoformans isolates from southern Taiwan and their in vitro susceptibilities to amphotericin B, fluconazole, and voriconazole.
    Chang WN; Huang CR; Lei CB; Lee PY; Chien CC; Chang HW; Chang CS; Lu CH
    Jpn J Infect Dis; 2004 Jun; 57(3):113-5. PubMed ID: 15218221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current scenario of cryptococcosis and antifungal susceptibility pattern in India: a cause for reappraisal.
    Capoor MR; Mandal P; Deb M; Aggarwal P; Banerjee U
    Mycoses; 2008 May; 51(3):258-65. PubMed ID: 18399907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The efficacy of self-assembled cationic antimicrobial peptide nanoparticles against Cryptococcus neoformans for the treatment of meningitis.
    Wang H; Xu K; Liu L; Tan JP; Chen Y; Li Y; Fan W; Wei Z; Sheng J; Yang YY; Li L
    Biomaterials; 2010 Apr; 31(10):2874-81. PubMed ID: 20044131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rates of antifungal resistance among Spanish clinical isolates of Cryptococcus neoformans var. neoformans.
    Perkins A; Gomez-Lopez A; Mellado E; Rodriguez-Tudela JL; Cuenca-Estrella M
    J Antimicrob Chemother; 2005 Dec; 56(6):1144-7. PubMed ID: 16282208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antifungal susceptibility of Cryptococcus neoformans and Cryptococcus gattii isolates from decayed wood of trunk hollows of Ficus religiosa and Syzygium cumini trees in north-western India.
    Khan ZU; Randhawa HS; Kowshik T; Chowdhary A; Chandy R
    J Antimicrob Chemother; 2007 Aug; 60(2):312-6. PubMed ID: 17553813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Susceptibility profile and epidemiological cut-off values of Cryptococcus neoformans species complex from Argentina.
    Córdoba S; Isla MG; Szusz W; Vivot W; Altamirano R; Davel G
    Mycoses; 2016 Jun; 59(6):351-6. PubMed ID: 26865081
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of amphotericin B in combination with flucytosine against flucytosine-susceptible or flucytosine-resistant isolates of Cryptococcus neoformans during disseminated murine cryptococcosis.
    Schwarz P; Dromer F; Lortholary O; Dannaoui E
    Antimicrob Agents Chemother; 2006 Jan; 50(1):113-20. PubMed ID: 16377675
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro susceptibility of Cryptococcus gattii clinical isolates.
    Gomez-Lopez A; Zaragoza O; Dos Anjos Martins M; Melhem MC; Rodriguez-Tudela JL; Cuenca-Estrella M
    Clin Microbiol Infect; 2008 Jul; 14(7):727-30. PubMed ID: 18558948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular typing and antifungal susceptibility of clinical sequential isolates of Cryptococcus neoformans from Sao Paulo State, Brazil.
    Almeida AM; Matsumoto MT; Baeza LC; de Oliveira E Silva RB; Kleiner AA; Melhem Mde S; Mendes Giannini MJ;
    FEMS Yeast Res; 2007 Jan; 7(1):152-64. PubMed ID: 17311593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adaptation to Fluconazole via Aneuploidy Enables Cross-Adaptation to Amphotericin B and Flucytosine in Cryptococcus neoformans.
    Yang F; Gritsenko V; Lu H; Zhen C; Gao L; Berman J; Jiang YY
    Microbiol Spectr; 2021 Oct; 9(2):e0072321. PubMed ID: 34585947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The combination of tamoxifen with amphotericin B, but not with fluconazole, has synergistic activity against the majority of clinical isolates of Cryptococcus neoformans.
    Hai TP; Van AD; Ngan NTT; Nhat LTH; Lan NPH; Vinh Chau NV; Thwaites GE; Krysan D; Day JN
    Mycoses; 2019 Sep; 62(9):818-825. PubMed ID: 31173410
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced diallyl trisulfide has in vitro synergy with amphotericin B against Cryptococcus neoformans.
    Shen J; Davis LE; Wallace JM; Cai Y; Lawson LD
    Planta Med; 1996 Oct; 62(5):415-8. PubMed ID: 8923805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of amphotericin B with flucytosine is active in vitro against flucytosine-resistant isolates of Cryptococcus neoformans.
    Schwarz P; Janbon G; Dromer F; Lortholary O; Dannaoui E
    Antimicrob Agents Chemother; 2007 Jan; 51(1):383-5. PubMed ID: 17043122
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antifungal drug combinations for Cryptococcus neoformans and Prototheca spp.
    Srimuang S; Prariyachatigul C; Chaiprasert A; Rungsipanuratn W; Tanphaichitra D
    J Med Assoc Thai; 2000 Jan; 83(1):57-60. PubMed ID: 10710870
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.